Wells Fargo analyst Derek Archila lowered the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $46 and keeps an Overweight rating on the shares following quarterly results. Given the recent pullback, Wells thinks shares can work into management’s year-end 2023 update on its subcu decision/path forward and positive read-through from Horizon Therapeutics’ (HZNP) Tepezza sales ramp in chronic TED.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRDN:
- Viridian Therapeutics reports Q2 EPS ($1.27), consensus ($1.29)
- VRDN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Viridian Therapeutics files to sell 244K shares of common stock for holders
- Viridian Therapeutics management to meet virtually with Jefferies
- Viridian Therapeutics’ VRDN-001 data may keep enthusiasm in check, says RBC
